Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could popular Weight-Loss drugs harm your teeth? a new study investigates

NCT ID NCT07720466

Knowledge-focused Sponsor: Bilecik Seyh Edebali Universitesi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This study looks at whether GLP-1 receptor agonists like semaglutide and tirzepatide, used for weight loss, change saliva composition and increase tooth wear. Researchers will measure saliva calcium, pH, flow rate, and dental erosion in 40 adults before and 3 months after starting the medication. The goal is to understand potential oral health side effects and help clinicians prevent dental complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide or tirzepatide (GLP-1 receptor agonists)
What this could lead to
If it finds clear links, this could help doctors monitor and prevent dental problems in people taking GLP-1 drugs for obesity.
What could go wrong
This is a small, early observational study with only 40 participants and no control group, so results may not apply broadly. It measures changes over just 3 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of adults (≥18 years) with obesity (BMI ≥27 kg/m²) who are prescribed semaglutide or tirzepatide for obesity management according to routine clinical practice. Participants will be recruited before initiating GLP-1 receptor agonist therapy at the Endocrinology and Metabolism outpatient clinic and will undergo standardized oral examinations and saliva assessments at baseline and after 3 months of treatment.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older. * Body mass index (BMI) ≥27 kg/m². * Clinical decision by an endocrinologist to initiate semaglutide or tirzepatide therapy for obesity management. * No previous treatment with GLP-1 receptor agonists. * Willingness to participate and ability to provide written informed consent. * Willingness to attend both the baseline and 3-month follow-up visits. Exclusion Criteria: * Previous use of any GLP-1 receptor agonist. * History of head and neck radiotherapy. * Sjögren syndrome or other systemic diseases affecting salivary gland function. * Chronic kidney disease. * Pregnancy or breastfeeding. * Use of medications known to markedly affect salivary secretion. * Active orthodontic treatment. * Severe dental erosion requiring restorative treatment at baseline. * Edentulism or the absence of anterior teeth required for dental hard tissue assessment. * Inability or unwillingness to comply with the study protocol or attend the 3-month follow-up visit. * History of eating disorders associated with recurrent self-induced vomiting (e.g., bulimia nervosa). * Medical conditions causing persistent vomiting or severe gastroesophageal disease unrelated to GLP-1 therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dental erosion are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder tooth erosion, non-bacterial

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dental erosion Obesity Saliva altered Saliva collection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Periodontology, Bilecik Seyh Edebali University Faculty of Dentistry

    Bilecik, Merkez, 11100, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.